Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aldeyra Therapeutics, Inc.

< Previous 1 2 3 Next >
Aldeyra Therapeutics Announces Positive Results from Phase 2 Clinical Trial in Alcohol-Associated Hepatitis, Focuses RASP Product Candidate Pipeline on Next-Generation Molecules
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Primary Large B-Cell Lymphomas of Immune-Privileged Sites, including Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Receives Fast Track Designation for ADX‑2191 for the Treatment of Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Receives Orphan Designation from the European Medicines Agency for ADX-2191 for the Treatment of Inherited Retinal Dystrophies including Retinitis Pigmentosa
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Receives Special Protocol Assessment Agreement Letter from the U.S. Food and Drug Administration for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the 2025 Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Appoints Chip Clark to Board of Directors
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the 2025 Leerink Partners Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the Citi 2024 Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces FDA Acceptance for Review of Reproxalap New Drug Application for the Treatment of Dry Eye Disease, Expands AbbVie Option Agreement
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Host Investor Roundtable Q&A
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
From Aldeyra Therapeutics, Inc.
Via Business Wire
Tickers ALDX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.